BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 21133722)

  • 1. Evaluation of anti-human leukocyte antigen-DR monoclonal antibody therapy in spontaneous canine lymphoma.
    Stein R; Balkman C; Chen S; Rassnick K; McEntee M; Page R; Goldenberg DM
    Leuk Lymphoma; 2011 Feb; 52(2):273-84. PubMed ID: 21133722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.
    Stein R; Qu Z; Chen S; Solis D; Hansen HJ; Goldenberg DM
    Blood; 2006 Oct; 108(8):2736-44. PubMed ID: 16778139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMab.
    Zhao L; Xie F; Tong X; Li H; Chen Y; Qian W; Duan S; Zheng J; Zhao Z; Li B; Zhang D; Zhao J; Dai J; Wang H; Hou S; Guo Y
    MAbs; 2014; 6(3):740-8. PubMed ID: 24670986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humanization and characterization of the anti-HLA-DR antibody 1D10.
    Kostelny SA; Link BK; Tso JY; Vasquez M; Jorgensen BH; Wang H; Hall WC; Weiner GJ
    Int J Cancer; 2001 Aug; 93(4):556-65. PubMed ID: 11477560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
    Liu C; DeNardo G; Tobin E; DeNardo S
    Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo destruction of canine lymphoma mediated by murine monoclonal antibodies.
    Steplewski Z; Rosales C; Jeglum KA; McDonald-Smith J
    In Vivo; 1990; 4(4):231-4. PubMed ID: 2103365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IMMU-140, a Novel SN-38 Antibody-Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma.
    Cardillo TM; Govindan SV; Zalath MB; Rossi DL; Wang Y; Chang CH; Goldenberg DM
    Mol Cancer Ther; 2018 Jan; 17(1):150-160. PubMed ID: 29133623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A selective high affinity ligand (SHAL) designed to bind to an over-expressed human antigen on non-Hodgkin's lymphoma also binds to canine B-cell lymphomas.
    Balhorn RL; Skorupski KA; Hok S; Balhorn MC; Guerrero T; Rebhun RB
    Vet Immunol Immunopathol; 2010 Oct; 137(3-4):235-42. PubMed ID: 20576295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells.
    Nagy ZA; Hubner B; Löhning C; Rauchenberger R; Reiffert S; Thomassen-Wolf E; Zahn S; Leyer S; Schier EM; Zahradnik A; Brunner C; Lobenwein K; Rattel B; Stanglmaier M; Hallek M; Wing M; Anderson S; Dunn M; Kretzschmar T; Tesar M
    Nat Med; 2002 Aug; 8(8):801-7. PubMed ID: 12101408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diversity of anti-HLA-DR antibodies elicited by distinct anti-idiotypic monoclonal antibodies recognizing idiotopes co-expressed by the immunizing monoclonal antibody.
    Mariani SM; Armandola EA; Ferrone S
    Immunology; 1992 Dec; 77(4):597-603. PubMed ID: 1283602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a candidate therapeutic antibody for treatment of canine B-cell lymphoma.
    Rue SM; Eckelman BP; Efe JA; Bloink K; Deveraux QL; Lowery D; Nasoff M
    Vet Immunol Immunopathol; 2015 Apr; 164(3-4):148-59. PubMed ID: 25764941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3).
    Demanet C; Brissinck J; Van Mechelen M; Leo O; Thielemans K
    J Immunol; 1991 Aug; 147(3):1091-7. PubMed ID: 1830596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.
    Würflein D; Dechant M; Stockmeyer B; Tutt AL; Hu P; Repp R; Kalden JR; van de Winkel JG; Epstein AL; Valerius T; Glennie M; Gramatzki M
    Cancer Res; 1998 Jul; 58(14):3051-8. PubMed ID: 9679970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways.
    Stein R; Gupta P; Chen X; Cardillo TM; Furman RR; Chen S; Chang CH; Goldenberg DM
    Blood; 2010 Jun; 115(25):5180-90. PubMed ID: 20101022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR.
    Zeng J; Liu R; Wang J; Fang Y
    J Cancer Res Clin Oncol; 2015 Nov; 141(11):1899-907. PubMed ID: 25773122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diversity in the fine specificity and idiotypic profile of mouse anti-HLA-DR monoclonal antibody elicited with the syngeneic anti-idiotypic monoclonal antibody F5-830.
    Mariani SM; Armandola EA; Ferrone S
    J Immunol; 1991 Aug; 147(4):1322-30. PubMed ID: 1714480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and immunological studies in advanced cancer patients sequentially treated with anti CD3 monoclonal antibody (OKT3) and interleukin-2.
    Borrione P; Montacchini L; Beggiato E; Pileri A; Bianchi A; Massaia M
    Leuk Lymphoma; 1996 Apr; 21(3-4):325-30. PubMed ID: 8726415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fully human antibody exhibits pan-human leukocyte antigen-DR recognition and high in vitro/vivo efficacy against human leukocyte antigen-DR-positive lymphomas.
    Tawara T; Hasegawa K; Sugiura Y; Tahara T; Ishida I; Kataoka S
    Cancer Sci; 2007 Jun; 98(6):921-8. PubMed ID: 17428256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells.
    Rossi EA; Rossi DL; Stein R; Goldenberg DM; Chang CH
    Cancer Res; 2010 Oct; 70(19):7600-9. PubMed ID: 20876805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice.
    de Kroon JF; de Paus RA; Kluin-Nelemans HC; Kluin PM; van Bergen CA; Munro AJ; Hale G; Willemze R; Falkenburg JH
    Exp Hematol; 1996 Jul; 24(8):919-26. PubMed ID: 8690051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.